Tag: KIN

business, Finance

Biotech Bullish stocks: Oragenics (NYSEMKT:OGEN), Kindred Biosciences (NASDAQ:KIN), Revance Therapeutics (NASDAQ:RVNC), Stemline Therapeutics (NASDAQ:STML), Aastrom Biosciences (NASDAQ:ASTM)

On May 30, 2014 Oragenics Inc (NYSEMKT:OGEN) held its Annual meeting of Shareholders (the “Meeting”), at which Meeting, the Company’s shareholders authorized the amendment to our Amended and Restated Articles of Incorporation (the “Amendment”) to increase the number of authorized common stock to 100,000,000 shares, upon a determination by our Board of Directors that such an increase is in the best interests of our Company … Continue reading Biotech Bullish stocks: Oragenics (NYSEMKT:OGEN), Kindred Biosciences (NASDAQ:KIN), Revance Therapeutics (NASDAQ:RVNC), Stemline Therapeutics (NASDAQ:STML), Aastrom Biosciences (NASDAQ:ASTM)

Mark Doerr
Finance

Biotech Volatile Stocks: NewLink Genetics Corp (NASDAQ:NLNK), Alnylam Pharmaceuticals (NASDAQ:ALNY), Kindred Biosciences (NASDAQ:KIN), Agenus (NASDAQ:AGEN)

NewLink Genetics Corp (NASDAQ:NLNK)’s algenpantucel-L is expected to garner the highest sales and will be launched in both resectable and unresectable locally-advanced settings. Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck’s TH-302 and Merrimack Pharmaceuticals’ MM-398,” director says. NewLink Genetics Corp (NASDAQ:NLNK) stock performance was -9.03% in last session and finished the day at $24.98. Traded volume was 808,573.00million shares in the … Continue reading Biotech Volatile Stocks: NewLink Genetics Corp (NASDAQ:NLNK), Alnylam Pharmaceuticals (NASDAQ:ALNY), Kindred Biosciences (NASDAQ:KIN), Agenus (NASDAQ:AGEN)

John Bellich
BioTech

Biotech Stocks New Highs: Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN), Celladon Corp (NASDAQ:CLDN), Kindred Biosciences (NASDAQ:KIN)

Fate Therapeutics, Inc. (NASDAQ:FATE) announced that it has enrolled the first patient in its phase II study (PUMA − P rohema in UM bilical cord blood transplant in A dults) on Prohema. Fate Therapeutics Inc. (NASDAQ:FATE) stock performance was 27.14% in last session and finished the day at $11.15. Traded volume was 295,227.00 shares in the last session and the average volume of the stock … Continue reading Biotech Stocks New Highs: Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN), Celladon Corp (NASDAQ:CLDN), Kindred Biosciences (NASDAQ:KIN)

Colin Pettis